Michelle W. | Leland

Michelle W.

HBS Grad who pivoted into VC from startups

Studied at University of Chicago

Works at Wavemaker 360

Available tomorrow at 1:00 AM UTC

Protected by the Leland Experience Guarantee

Available tomorrow at 1:00 AM UTC

Questions? Start chatting with this coach before you get started.

Michelle's Coaching Offerings

Land a Top Venture Capital Offer: Start-to-Finish

Expert help on everything from getting the interview to landing the offer.

Starting at $65010h+ of coaching

Custom hourly

Get help with Skill Building, Venture Capital Strategy, and .

Michelle also coaches for MBA and Career Coaching. View all.

Michelle’s Venture Capital Qualifications

Experience level: Senior Associate

I spent the last few years exploring how to pivot into VC particularly since the market took a turn. Ultimately, I was able to get an offer from my top choice dream fund. Through this process, I've seen how the experience differs across fund types, and can help think through what kinds of funds you're interested in, and how to target your efforts to secure an offer.

Michelle can help with:

Skill Building

Venture Capital Strategy

Deal Sourcing

Resume Review

Networking Strategy

Due Diligence

Investment Evaluation

Salary Negotiation

Behavioral Interview Prep

Michelle also coaches for MBA and Career Coaching. View all.

Work Experience

Health Tech Investor

Wavemaker 360

January 2025 - Present

Wavemaker Three-Sixty Health is the leading U.S. early stage (Seed and Series A) venture capital fund focused 100% on healthcare. We're backed by healthcare LPs - both leading organizations and healthcare professionals - across providers (throughout the continuum of care), payers and pharma. This gives us a unique advantage when it comes to discovering compelling healthcare startups, evaluating their business models and investability, and most importantly, commercially supporting these early-stage health-tech companies. We invest in healthcare IT, digital health, medical device, pharma-tech, AI and science - we do not invest in bio-pharma. Currently deploying capital out of Fund III.